https://www.selleckchem.com/pr....oducts/ch4987655.htm
There is also evidence for targeting inflammatory pathways to control other autoimmune conditions, such as blockade of IL1 and IL6 and Janus-associated kinase (JAK) inhibitors. With the range of tools available to clinicians and patients increasing, it is likely that the therapeutic landscape of AIH will change over the coming years and treatment approaches offering lower corticosteroid use and aiming to restore immune self-tolerance should be sought. With the range of tools available to clinicians and patients increasing, it is likel
Like
Comment
Share
